Semaglutide
5 mg
$39.00
Cagrilintide 5 mg + Semaglutide 5 mg combo blend, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
For use by licensed and trained professionals only, operating within their applicable regulations. Not evaluated by the FDA.
Cagrilintide 5 mg + Semaglutide 5 mg combo blend, supplied as a lyophilized powder vial paired with a separate vial of bacteriostatic water for reconstitution. Shipped with full cold-chain handling.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
| Available sizes | 5 mg + 5 mg — $89.00 |
| Form | Lyophilized powder + BAC water vial |
| Molecular weight | 4409.0 / 4113.6 g/mol |
| CAS | 1415456-99-3 / 910463-68-2 |
| Sequence length | — |
| Storage — sealed | −20 °C, protected from light |
| Storage — reconstituted | 2–8 °C, use within 14 days |
| Ships from | Chicago, IL |
| SKU | GLP-CAGRISEMA-55 |
Research summary — for laboratory and research use only. Not medical advice, not a dosing recommendation, and not an FDA evaluation of safety or efficacy.
This blend mirrors Novo Nordisk's investigational "CagriSema" combination — cagrilintide paired with semaglutide — studied through the REDEFINE Phase 3 program as a combined amylin/GLP-1 receptor strategy for weight management.
Combining an amylin-receptor agonist (cagrilintide) with a GLP-1 receptor agonist (semaglutide) is intended to act on two complementary appetite- and satiety-regulating pathways at once. Published Phase 3 data on the branded CagriSema combination has reported greater average weight loss than semaglutide alone in the same trial population.
The REDEFINE program is the primary reference dataset for this specific two-receptor combination strategy.
Used as a research comparator against single-agonist GLP-1 therapies and against triple-agonist molecules like retatrutide.
Supplied to licensed and trained professionals only, operating within their applicable regulations. Keep refrigerated at 2–8 °C both before and after reconstitution; do not freeze. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
No — this is a research-grade combination vial mirroring that investigational ratio, supplied unapproved and strictly for research/professional use, not the Novo Nordisk clinical product.
Further reading: for the published preclinical and clinical literature on Cagrilintide + Semaglutide, search PubMed. We link to the search rather than cherry-picked citations so you can review the current, full body of literature yourself.